Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life-Reference-Cited by-同舟云学术

Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life

Published:2019-06 Issue:9 Volume:11 Page:783-794
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Caminati Marco¹²,Arcolaci Alessandra¹,Guerriero Massimo³,Manzotti Giuseppina⁴,Crivellaro Mariangiola⁵,Rolla Giovanni⁶⁷,Fassio Filippo⁸,Senna Gianenrico¹

Affiliation:

1. Asthma Center & Allergy Unit, Verona University & General Hospital, Verona, Italy

2. Department of Medicine, Allergy and Clinical Immunology School, University of Verona, Verona, Italy

3. Department of Computer Science, University of Verona, Verona, Italy

4. Allergy Outpatient Clinic, Treviglio Hospital, Treviglio, Bergamo, Italy

5. Allergy service, Department of Environmental Medicine & Public Health, Padua University & General Hospital, Padua, Italy

6. Department of Medical Science, University of Torino, Italy

7. Allergy & Clinical Immunology Uni, A.O. Ordine Mauriziano, Torino, Italy

8. Allergy & Clinical Immunology Unit, Azienda Usl Toscana Centro, Ospedale San Giovanni di Dio, Firenze, Italy

Abstract

Aim: We assessed the safety of allergoid adjuvanted by monophosphoryl lipid A (uSCIT-MPL-4) in a real-life setting. Materials & methods: Patients treated with uSCIT-MPL-4 were followed-up for 1 year. Systemic reactions (SRs) were registered and the association with potential risk factors was evaluated. Results: 2929 patients were included. Grade 0, 1, 2, 3 and 4 SR reactions were observed respectively in 3.3, 1.5, 0.31, 0.07 and 0.07% of patients. A significant association was detected between Grade ≥1 SRs and: female gender, number of administrations, previous local reactions. Conclusion: uSCIT-MPL-4 is safe. Local reactions should be accurately assessed as they may represent a risk factor for Grade ≥1 SRs, together with gender and number of doses/year.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2019-0009

Reference46 articles.

1. Advantages and disadvantages of accelerated immunotherapy schedules

2. Allergen immunotherapy: Present and future

3. Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy

4. Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases

5. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of subcutaneous and sublingual immunotherapy with allergoids in children: a real-life pharmacovigilance study;Immunotherapy;2024-01

2. MicroCrystalline Tyrosine-adsorbed immunotherapy;Current Opinion in Allergy & Clinical Immunology;2022-10-10